Aronica Williams
Family Medicine · Milwaukee, WINPI 1447318530
Payments from drug & device makers
Across 87 payments — averaging $17.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$227
- Pfizer$191
- Gilead$141
- Boehringer Ingelheim$115
- AstraZeneca$111
- Sanofi Pasteur Inc.$95
- plus $654 from 20 others
What the payments were for
- Food & beverage$1,534100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 19 | $227 |
| Pfizer | 11 | $191 |
| Gilead | 2 | $141 |
| Boehringer Ingelheim | 7 | $115 |
| AstraZeneca | 5 | $111 |
| Sanofi Pasteur Inc. | 5 | $95 |
| Novo Nordisk | 6 | $90 |
| Exact Sciences | 3 | $81 |
| GSK | 4 | $78 |
| Merck | 4 | $67 |
| Novartis | 2 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Scilex Pharmaceuticals Inc. | 2 | $32 |
| Biogen | 1 | $29 |
| Phathom Pharmaceuticals, Inc. | 1 | $28 |
| Aimmune Therapeutics, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Agile Therapeutics, Inc. | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Cranial Technologies, Inc | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $14 |
| Lilly USA, LLC | 1 | $12 |
| Johnson & Johnson | 1 | $11 |
| Ultragenyx Pharmaceutical Inc. | 2 | $10 |
How this compares
$1,534 in reported general payments places this provider in the 90th percentile of 1,482 family medicine providers in Wisconsin.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TradjentaLinagliptin | 42 | $23,390 |
| LinzessLinaclotide | 32 | $20,290 |
| JanuviaSitagliptin Phosphate | 14 | $8,040 |
| Atorvastatin Calcium | 213 | $1,627 |
| Febuxostat | 26 | $1,529 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 53 | $1,239 |
| Amlodipine Besylate | 200 | $1,051 |
| Rosuvastatin Calcium | 58 | $995 |
| Gabapentin | 52 | $692 |
| Omeprazole | 55 | $659 |
| Fluticasone Propionate | 29 | $588 |
| Losartan Potassium | 74 | $473 |
| Metoprolol Succinate | 50 | $449 |
| Lisinopril | 59 | $437 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 38 | $407 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTradjenta | $115 | $23,39042 claims |
| AbbVieLinzess | $227 | $20,29032 claims |
| MerckJanuvia | $67 | $8,04014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,482 family medicine providers in Wisconsin.
Other family medicine in Milwaukee
- William PalinMilwaukee$693K
- Mario KapetsonisMilwaukee$123K
- Syed AhmedMilwaukee$78K
- Steven BondowMilwaukee$34K
- Suresh MisraMilwaukee$16K
- Ramneet BhathalMilwaukee$12K
- Roland WillockMilwaukee$7K
- Taha El-ShahatMadison$15.6M
- Jonathan MeimanMadison$4.3M
- John AgaibyKenosha$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.